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Modeling disease with human pluripotent stem cells (hPSCs) is hindered because the impact on cell phenotype from
genetic variability between individuals can be greater than from the pathogenic mutation. While ‘‘footprint-free’’ Cas9/
CRISPR editing solves this issue, existing approaches are inefficient or lengthy. In this study, a simplified PiggyBac
strategy shortened hPSC editing by 2 weeks and required one round of clonal expansion and genotyping rather than two,
with similar efficiencies to the longer conventional process. Success was shown across four cardiac-associated loci
(ADRB2, GRK5, RYR2, and ACTC1) by genomic cleavage and editing efficiencies of 8%–93% and 8%–67%, re-
spectively, including mono- and/or biallelic events. Pluripotency was retained, as was differentiation into high-purity
cardiomyocytes (CMs; 88%–99%). Using the GRK5 isogenic lines as an exemplar, chronic stimulation with the b-
adrenoceptor agonist, isoprenaline, reduced beat rate in hPSC-CMs expressing GRK5-Q41 but not GRK5-L41; this was
reversed by the b-blocker, propranolol. This shortened, footprint-free approach will be useful for mechanistic studies.
Keywords: Cas9/CRISPR, PiggyBac, gene editing, human pluripotent stem cells, genetic disease modeling,
cardiomyocytes
Introduction
Human pluripotent stem cells (hPSCs) compriseboth human embryonic stem cells (hESCs), derived
from the inner cell mass of the preimplantation embryo, and
human-induced pluripotent stem cells (hiPSCs), derived by
epigenetic reprogramming of somatic cells [1]. It is now well
established that hPSCs are an important modality for biomed-
icine, with application ranging from understanding human de-
velopment through to use of their differentiated progeny in
safety assessment of drugs, accelerating drug use toward clinic
and modeling genetic disease [1]. Suitability in several clinical
trials has been, or is being evaluated, including for spinal cord
injury, macular degeneration, and heart disease [2]. A difficulty
that has emerged for the in vitro assays is that genetic variation
between unrelated individuals may cause greater phenotypic
differences than do the disease-associated polymorphism(s) [3].
Therefore, creation of isogenic pairs, wherein only the poly-
morphism of interest differs between lines, is now considered
the gold standard. While the number of reports using conven-
tional gene targeting in hPSC is low, the advent of nuclease-
mediated targeting, particularly with Cas9/CRISPR, has made
precise modification of the genome relatively routine [1].
Despite these advances, difficulties still remain in gene
editing of hPSCs. Making single base-pair substitutions is
technologically challenging when compared to, for example,
gene knockouts, where libraries of guide RNAs (gRNAs) are
being used in functional genome-wide screens [4]. An im-
portant consideration for editing is that, other than the desired
polymorphic changes, the level of genome modification
postgene-edited hPSC line should be minimal. This is be-
cause residual footprints left behind after targeting can alter
or abolish neighboring gene expression [1,5,6]. This advo-
cates the use of footprint-free or scarless approaches.
One route to achieving footprint-free editing is via the de-
livery of ribonucleoprotein combinations that comprise re-
combinant Cas9 protein, in vitro transcribed gRNA and a
*50–150 base single-stranded DNA oligonucleotide (ssODN)
template, which carries the polymorphic change(s) of interest
[7]. We demonstrated the utility of this approach by modifying
theADRB2 locus, which encodes the b2-adrenocetor [1], while
others have altered additional loci [7,8]. Although this route is
attractive and less toxic than plasmid approach [7], it requires
high transfection rates of large complexes, which can be dif-
ficult in sensitive cells such as hPSCs. The lack of a drug
selection marker also means that considerable screening effort
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is needed to identify positive clones. An alternative to achieving
seamless editing by using ssODNs as a template is via a system
termed ‘‘CORRECT’’ [9]; however, this requires two sequential
clonal selection/expansion steps.
An alternative for footprint-free editing is the PiggyBac
transposon system [10], although this does require a TTAA
quadranucleotide site for recombination (Fig. 1). In this
approach, a targeting vector contains a positive–negative
drug selection cassette (eg, Puro-DTK; Fig. 1A) that is
flanked by PiggyBac recombination sites. In turn, these
components are flanked by regions of up to 1 kb in length
that are homologous to the endogenous target locus, thus
enabling recombination between template and genome.
The desired polymorphism(s) is carried within one arm of
homology.
Experimentally, the approach is implemented via two se-
quential steps. First, the targeting vector is cotransfected with
plasmids carrying guide RNA and Cas9 to promote genomic
cleavage and insertion via homology-directed repair into the
locus of interest. Survival during positive selection with an-
tibiotics (eg, puromycin) identifies the hPSC clones that ex-
press the cassette, which are then picked, expanded, and
genotyped (Fig. 1B). Second, antibiotic-resistant hPSCs are
transfected with a plasmid expressing transposase, which
induces internal recombination between PiggyBac sites,
excision of the selection cassette, and reconstitution of a
footprint-free locus (Fig. 1B). Colonies that fail to excise the
cassette continue to express DTK and hence are negatively
selected against by the prodrugs, ganciclovir or fialuridin.
This leaves the surviving colonies, which can be picked,
expanded, and genotyped for a second time.
Several reports have described the successful use of
this PiggyBac approach in hPSC [11–13]. Nevertheless, the
requirement for two rounds of clonal selection and geno-
typing over a lengthy timeline is problematic. Particularly
for hPSCs, the number of cumulative population doublings
correlates genetic [14] and epigenetic [15,16] instabil-
ity, thereby affecting their downstream applications [17].
Similarly, in mouse iPSCs, genetic instability has been
reported within as few as 4–6 passages [18]. Thus, pro-
cesses that enable gene editing in shorter timelines would
be beneficial [19].
In this report, we adapted a footprint-free PiggyBac-
based Cas9/CRISPR gene editing strategy to both simplify
and shorten the process. Only one round of clonal selection
and genotyping is needed, reducing the process from 49 to
35 days, a 25%–30% time saving that equates to *14
population doublings in hPSCs. We have demonstrated the
utility of this simplified approach by making single or dual
polymorphic changes to four cardiac-related genes, ADRB2,
GRK5, RYR2, and ACTC1. For each of the engineered hPSC
lines created, we showed that the cells retained expression of
pluripotency markers, a stable karyotype, and the ability to
differentiate at high efficiency into beating cardiomyocytes
(CM) that express a-actinin. As an exemplar, we showed
significant differences in functional consequence between
isogenic pairs of hiPSC-CMs that carry GRK5-L41 or GRK5-
Q41 polymorphisms in response to chronic b-adrenergic
stimulation and b-blocker rescue. Thus, the approach de-
scribed provides a simplified and abbreviated route toward
mechanistic understanding of how single polymorphic
variants alter heart function.
Materials and Methods
Cell culture
All cultures were at 37C at 5% CO2 in a humidified
atmosphere. Unless otherwise stated, all reagents were from
ThermoFisher. HUES7 hESCs were gifted by Chad Cowan
and Doug Melton at the Harvard Stem Cell Institute. Fibro-
blasts were derived under ethical consent from individual with
the genotypes RYR26739C/T (NRES Committee East Midlands–
Nottingham 2 approval 09/H0408/74) and ACTC1301G/G
(Biomedical Institute of A Coruna, INIBIC). Reprogramming
to hiPSCs was via CytoTune 2.0 (ThermoFisher), according
to the manufacturer’s instructions. Culture was in E8 medium
on Matrigel, although processes could also be completed in
hESC medium conditioned using mouse embryonic fibro-
blasts [20]. In the first 4–5 passages after reprogramming,
cell harvesting was done using 0.5 mM EDTA and there-
after with accutase.
Transfection optimization
For transfection and electroporation experiments, hPSCs
were seeded at 3· 105 cells/well of the Matrigel-coated 6-well
plate or resuspended cells at 2· 105 cell/well/transfection con-
dition in Nucleocuvette Strip (16 wells), respectively. Plasmids
were transfected into hPSCs using FuGene HD transfection
reagent (E2311; Promega) following the manufacturer’s in-
structions, using a ratio between reagent and plasmid DNA of
4:1. To optimize the electroporation using the Amaxa 4D sys-
tem (Lonza), pmaxGFP plasmid provided in the Lonza Amaxa
4D Kit was transfected into hPSCs with human stem cell P3
solution (programs: CA-137, CB-150, CD-1118, CE-118, CM-
113, DC-100, DN-100, as recommended by the manufacturer’s
protocol). The green fluorescent protein signal was captured
using Operetta High-Content Imaging System (Perkin Elmer)
and analyzed using Harmony High-Content Imaging Software.
Targeting vector construction
The ADRB2 targeting vector was constructed via Gibson
assembly by using Gibson Assembly Master Mix (E2611S
NEB). Overlapping fragments were produced by polymerase
chain reaction (PCR) (GoTaq polymerase; Promega) for three
inserts: Dual drug selection cassette (Puro-DTK) flanked by
PiggyBac recombination sites and the left and right homology
regions for ADRB2 (*1 kb upstream and *1 kb downstream
of the locus cut site). Primers used are shown in Supple-
mentary Table S1 (Supplementary Data are available online
at www.liebertpub.com/scd). An EcoRV-digested pBluescript
backbone plasmid sequence was used as the fourth DNA
fragment in the Gibson assembly. A 20mL reaction contain-
ing 0.24 pmol of each insert, 0.08 pM of Bluescript backbone,
and 1·Gibson Assembly Master Mix (NEB) was heated at
50C for 60 min. Subsequent transformation into Top10
competent cells and colony sequencing identified correctly
assembled plasmids. The same approach was used to generate
the GRK5, ACTC1, and RYR2 targeting constructs.
Gene targeting in hPSCs
FuGene HD (Promega) transfection required seeding of
3 · 105 hPSCs into each well of a Matrigel-coated 6-well
plate. Twenty-four hours later, cells were transfected 3.3 mg
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of CRISPR plasmid components (targeting plasmid, gRNA,
Cas9). For Amaxa 4D nucleofection (Lonza), 3 · 106 hPSCs
and 3mg of CRISPR plasmid components were used with P3
solution, program CA-137. Transfected and nucleofected
cells were maintained in E8 medium on Matrigel (hESC
medium conditioned using mouse embryonic fibroblasts
[20] could also be used). Twenty-four hours posttransfec-
tion, medium was supplemented with puromycin (0.25–
7.5 mg/mL; cell line dependent) for positive selection of
clones up to 2 weeks. The puromycin-positive clones were
then harvested and expanded as described in the cell cul-
ture section. For cassette excision, cells were seeded at
3 · 105 cells/well of a Matrigel-coated 6-well plate before
delivering transposase plasmid by transfection (3 mg) using
FuGene HD transfection as described above. Cells were
reseeded to 10 cm dishes, incubated for 2–3 days to allow
recombination by transposase and then exposed to medium
containing ganciclovir (2 mg/mL) for negative selection of
PiggyBac excision. Approximately 7–10 days later, clones
were manually dissected and genotyped using primers
shown in Supplementary Table S1. See this Table and also
Fig. 3 for location of primers to test for off-target and random
integration events. Real-time quantitative PCR (qPCR) to the
ampicillin gene was conducted by GoTag qPCR Master Mix
(No. A6001; Promega) on Applied Biosystems SDS 7500
Fast Real-time PCR template for 45 cycles. Melting curves
were obtained for all experimental runs. Relative expression
of genes was calculated and expressed as 2-DDCt, normal-
ized using 18S.
Characterization of hPSC
CM differentiation. Undifferentiated hPSCs were seeded
onto Matrigel-coated dishes at a density of 4 · 104 cells/cm2
and allowed to expand for 48 h (*80% confluency). At this
stage (d1 of differentiation), cultures were treated with me-
dium comprising StemPro34 supplemented with (1:100 dilu-
tion) Matrigel and (1 ng/mL) BMP4 (R&D systems) and after
24 h (d2 of differentiation), medium comprising StemPro34
with (10 ng/mL) BMP4 and (8 ng/mL) Activin A (Life
Technologies). Medium exchange was performed on d4 of
differentiation using RPMI supplemented with 1xB27 (Life
Technologies) and small molecule inhibitors, KY02111
(10 mM) and XAV939 (10 mM) (R&D systems). From d8
onward, cells were maintained in RPMI medium supp-
lemented with B27 only, with medium changes every
3 days. Cardiac differentiation efficiency was accessed by
using immunocytochemistry with primary mouse anti-human
a-actinin antibody (No. A7811, 1:800; Sigma) dilution and
secondary goat anti-rabbit Alexa633 (No. A21052, 1:400;
Invitrogen), counterstaining with 0.5 mg/mL DAPI (No.
D9542, 1:500; Sigma). Immunofluorescence images were
captured using Operetta High-Content System (Perkin El-
mer) and analyzed using Harmony High-Content Analysis
Software.
Gene expression. RNA was isolated from undifferenti-
ated hPSCs and derived CMs at day 14 of differentiation
using RNeasy Mini Kit (Qiagen). Synthesis of cDNA was
carried out using 1 mg RNA with SuperScript III Reverse
Transcriptase Kit (Invitrogen), according to manufactur-
er’s instructions. ADRB2 analysis was with TaqMan qPCR
(No. Hs00240532_s1; Applied Biosystems) and signals
were normalized to GAPDH (No. Hs99999905_m1; Ap-
plied Biosystems) as the housekeeping gene, following the
manufacturer’s instructions. Semi-qPCR cycle conditions
were 95C for 2 min, 64.5C for 30 s (GRK5, ACTC1,
RYR2, and ACTB), and 72C for 60 s, with a final elonga-
tion step of 72C for 10 min. Each reaction used 250 ng of
cDNA with Phusion polymerase (NEB) for 35 cycles. Gels
were imaged with a LAS-4000 (Fujifilm) image analyzer,
densitometry was carried out using FIJI, and a version of
ImageJ (National Institutes of Health) and signals were
normalized to ACTB as the housekeeping gene. Primers
for expression analysis are provided in Supplementary
Table S1.
Immunocytochemistry analysis of nuclear pluripotent
markers. hPSCs were cultured at 30,000 cells/cm2 in
Matrigel-coated 96-well plates (Perkin Elmer CellCarrier)
until reaching 60% confluent before fixing with 4% PFA.
Fixed cells were perforated using 0.01% Triton X-100 and
0.05% Tween 20 [(diluted in phosphate-buffered saline
(PBS)]. The cells were then incubated with mouse-anti
human OCT4 (C-10 clone; No. sc-5279, 1:100; Santa Cruz
Biotech) and subsequent secondary antibody using goat-
anti mouse Alexa488 (No. A11001, 1:1000; Invitrogen) and
counterstained with 0.5 mg/mL DAPI. Immunofluorescence
images were captured using Operetta High-Content System
(Perkin Elmer) and analyzed using Harmony High-Content
Analysis Software.
Flow cytometry analysis of surface pluripotent markers. To
analyze surface markers, hPSCs were harvested and fixed
using 4% PFA followed by incubation with phycoerythrin-
conjugated SSEA-1 (eBioMC-480 clone; No. 12-4752,
1:100; ThermoFisher), SSEA-4 (eBioMC-813-70 clone; No.
12-8843, 1:200; ThermoFisher), and TRA-1-81 (TRA-1-
81 clone; No. 12-8883, 1:100; ThermoFisher) antibodies
for 20 min at 4C. Cells were analyzed using an FC500
Flow cytometer (Beckman Coulter), and data were ana-
lyzed with FlowJo software.
Karyotyping. Metaphase spreads were prepared as pre-
viously described [20] from hPSCs after final genotype was
confirmed, and karyotype analysis was performed by G-
banding of 30 metaphase spreads in each sample, accord-
ing to guidelines from the International System for Human
Cytogenetic Nomenclature.
Functional analysis of GRK5 hPSC-CM
polymorphic variants
To measure the beat rate of CMs in real time, the Cardi-
oExcyte96 system (Nanion) was used. In brief, the 96-well
sensor plates of the CardioExcyte96 were coated by incuba-
tion (1.5 h) with fibronectin at 1:100 dilution in PBS (without
Ca2+ and Mg2+). CMs at d25 to d28 were dissociated and
seeded onto the sensor plate at 60,000 cells/well. Plates
were incubated for 48 h before changing the medium and
starting the recordings according to the following timeline:
0–2 h, baseline recording; 2 h, spike with 100 nM isoprena-
line; 24 h, repeat spike of isoprenaline; and 48–50 h, end of
recording. Beat rate of CMs was recorded throughout the
experiments at intervals of 2 to 10 min. For the nonselective
beta-blocker experiment, propranolol (200 nM) was added
1 h before starting isoprenaline treatment and maintained
throughout.
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Results
Locus selection and targeting strategy
for ADRB2 (b2-adrenoceptor)
Over the course of multiple experiments in our labora-
tory, we observed Cas9/CRISPR gene targeting efficiencies
of *30% (158 of 421 colonies assessed) across 12 different
loci and/or hPSC lines (data not shown) when using opti-
mized transfection conditions (Supplementary Fig. S1). In
the context of the two-step PiggyBac process, we reasoned
that the gene targeting efficiency during step 1 would be
rate limiting because cassette excision should occur in
most cells, provided transposase delivery is at high effi-
ciency at the start of step 2. An alternative strategy could be
to merge steps 1 and 2 of the PiggyBac process. This would
have the advantage of not only simplifying editing but also
of reducing the time to produce gene modified hPSCs by
14 days; this equates to *14 population doublings and
25%–30% of the whole targeting process (Fig. 1B).
To test this notion, we selected the ADRB2 locus for several
reasons. ADRB2 encodes b2-adrenoceptor, a G-protein cou-
pled receptor that has an N-terminal domain positioned in the
extracellular compartment. In this domain, two polymorphic
variants at amino acid positions p.Gly16Arg (c.G46A) and
p.Glu27Gln (c.G79C) alter patient response during heart fail-
ure [21]. Thus, production of isogenic hPSC lines from which
CMs can be produced would be beneficial in understanding the
mechanism of these differences. We also selected this locus
because it is expressed in undifferentiated hPSCs, although at
much lower levels than in hPSC-CMs (Fig. 1C). This may be
useful since an ‘‘open’’ configuration is considered to be more
permissible to gene targeting [22]. However, ADRB2 also re-
quires a footprint-free strategy because it is a single exon gene
with complex 5¢ and 3¢ untranslated regions, which include
multiple regulatory elements and domains required for proper
expression of ADRB2 and its membrane targeting [23–25]. As
such, positioning a selection cassette or a short footprint in
these regions may be disruptive to cell signaling and function,
even in the undifferentiated state.
The PiggyBac approach requires an endogenous quad-
ranucleotide TTAA palindrome sequence at the site of re-
combination, which theoretically occurs at 329 bp intervals
through the genome [26]. However, the PiggyBac transpo-
son has a preference for areas surrounding transcription start
sites and CpG islands [27], suggesting that even distribution
of TTAA sites does not occur. Supporting this notion, our
analysis of the genomic regions flanking the position 46 or
79 ADRB2 polymorphic variants in HUES7 hESCs revealed
that the nearest TTAA site was 748 bases away (data not
shown), which far exceeds the distance recommended for
insertion via nuclease-mediated targeting [10]. However, we
noted the sequence CTC ATC (nucleotide position 124–129)
situated 45 bases downstream of the position 79 polymor-
phism in ADRB2 coding sequence; codon redundancy for
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FIG. 1. PiggyBac targeting at the ADRB2 locus. (A) Shows a schematic of the ADRB2 locus structure before targeting, after
insertion of the PiggyBac positive–negative selection cassette and after cassette excision. The black (G/G) and red (A/C)
vertical lines indicate the location of the polymorphic changes induced at bases 46 and 79. Primer locations (b1, b2) for
genotyping are indicated, along with PCR product sizes. b2-L and b2-R indicate the left and right regions of homology, each
of 1 kb in length. (B) Shows the time line of the conventional two-step PiggyBac targeting approach (upper) and the simplified
approach (lower). In (C), expression of the ADRB2 gene was evaluated by quantitative real-time PCR in undifferentiated
hPSCs (U) and through a 66-day timecourse of directed monolayer differentiation to CMs; beating sheets appeared from
between d8-12. Data are mean–SEM; n= 4. CM, cardiomyocyte; hPSCs, human pluripotent stem cells; PB, PiggyBac; PCR,
polymerase chain reaction; PGK, phosphoglycerate kinase promoter; PURO, puromycin-N-acetyltransferase; TK, thymidine
kinase; TV, targeting vector. Color images available online at www.liebertpub.com/scd
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leucine meant that substitutions could be made to TTA ATC,
which created the TTAA site necessary for PiggyBac recom-
bination while being synonymous and retaining the native
Leu41-Ile42 peptide sequence (Fig. 2).
We sought to minimize any further changes, silent or
otherwise, to the ADRB2 locus. Therefore, we selected a
gRNA with a protospacer adjacent motif (PAM) overlapping
the polymorphic change c.G79C, ensuring cleavage of geno-
mic, but not targeting vector, sequences would occur (Fig. 2
and Supplementary Table S1). Thus, the left arm of homology
in the targeting vector contained c.G46A (p.Gly16Arg),
c.G79C (p.Glu27Gln), and c.C124T/c.C126A (synonymous:
p.Leu41-Ile42) modifications directed toward the ADRB2
locus (Figs. 1A and 2).
Simplified PiggyBac gene editing
in ADRB2 in hPSCs
The process outlined in Fig. 1 entails two steps, with gene
targeted insertion of the PiggyBac cassette and the associ-
ated polymorphic changes occurring in the first step, fol-
lowed by transposase-mediated cassette removal in the
second step. As we anticipated that cassette excision should
occur at high efficiency (Supplementary Fig. S1), we wished
to test whether the frequency and types of targeting events
were similar after first (midpoint) and second (end) steps. In
addition, we wanted to ensure that streamlining the process
by progressing directly from positive (puromycin) to nega-
tive (ganciclovir) selection did not have a detrimental effect.
HUES7 hESCs were cotransfected with Cas9, gRNA, and
ADRB2 targeting plasmids and then subjected to puromycin
treatment. Once early-stage drug-resistant colonies had
formed, a portion of the colonies were picked for geno-
typing after step 1. The remainder of the cells were har-
vested, transfected with transposase, and then treated with
ganciclovir, before allowing colonies to form for picking
and genotyping after step 2. All clones were assessed by
PCR amplification coupled to direct sequencing across the
left arm of homology (Fig. 3A, Supplementary Table S1,
and Supplementary Fig. S2A, B). Genotyping after first
versus second step showed high frequencies (Fig. 3B),
wherein genomic cleavage was evident in 8/11 (73%) and 6/
12 (50%). Specifically between categories 18% versus 8%
untargeted, 9% versus 8% monoallelic targeting, 9% versus
33% biallelic targeting, 55% versus 8% indels, indicated by
messy reads around Cas9 cleavage site, and 9% versus 42%
unclear result, indicated by PCR failure or lack of sequencing
data (Fig. 3A and Supplementary Fig. S2A, B).
We also evaluated off target events (Fig. 3C and Supple-
mentary Table S1). We focused on known coding or regulatory
sequences where gRNAs had full PAM site complementarily
and/or fewer than five mismatches with the target. The five
putative sites that met these criteria were shown by PCR am-
plification and sequencing to be unaffected by off targeting
(Fig. 3C). Therefore, the simplified PiggyBac approach was
successfully used to produce an isogenic set of wild type
(untargeted), heterozygote (monoallelic), and homozygote
(biallelic) dual-site modifications at nucleotide positions 46
and 79 in the 5¢ end of the ADRB2 gene in hESCs.
Finally, we tested for unwanted random integration
events of the vector elsewhere in the genome by PCR
(Fig. 3D). As expected, control primers that spanned the
PAM site in ADRB2 gave a product from parental cells and
after step 2, but not step 1, as the biallelic presence of a
complex puro-DTK cassette blocks the PCR. Correspond-
ingly, PCR products specific to the ADRB2-puro-DTK
junction and to DTK were produced only from step 1
samples, indicating that no residual targeting selection
cassette could be detected after transposase-mediated re-
moval. Remnants of the pBluescript plasmids backbone
were tested for by PCR to the ampicillin gene. No products
were seen by conventional PCR (data not shown). There-
fore, qPCR was carried out using a positive control,
wherein targeting plasmid DNA was diluted to the equiv-
alent of a single genomic copy into parental HUES7 DNA.
Relative to this positive control, samples from parental
cells, step 1 and step 2 gave a signal 10- to 20-fold lower.
Collectively, these data suggest that precise targeting of
FIG. 2. Polymorphic chan-
ges to the ADRB2 locus in
hPSCs. The nucleotide and
translated single-letter amino
acid sequences are shown for
the 5¢ region of the ADRB2
locus. The targeting strategy
introduces changes at posi-
tions 46 and 79 (nonsynon-
ymous in the peptide), and
124 and 126 (synonymous in
the peptide) as indicated.
Features identified are the
location of the gRNA under-
lined, with PAM site boxed,
and TTAA PiggyBac cassette
insertion site. PAM, proto-
spacer adjacent motif. Color
images available online at
www.liebertpub.com/scd
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the selection cassette occurred only at the ADRB2 locus
and not at random elsewhere in the genome, and cassette
excision occurs after transposase-mediated removal.
Applying simplified PiggyBac gene editing
to other cardiac-associated loci in hPSCs
Efficiency of gene targeting, including using Cas9/CRISPR,
is known to be influenced by genomic environment, including
complexity and GC-richness of gene sequence, active gene
expression, availability of sites to guide nuclease docking,
and cell type. Therefore, we selected three additional cardiac-
associated loci with different genetic properties, but each with
relevance to human health or heart disease (Fig. 4).
GRK5 encodes G-protein coupled receptor-specific ki-
nase involved in b-adrenergic receptor desensitization. It
has been suggested that a c.A122T (p.Gln41Leu) poly-
morphism causes a natural b-blocker effect that may be
protective against heart disease [28]. ACTC1 encodes car-
diac actin and a mutation at c.G301A (p.Glu101Lys) causes
hypertrophic cardiomyopathy, altered calcium sensitivity,
arrhythmias, and, in some cases, sudden cardiac death [29].
Finally, RYR2 encodes ryanodine receptor, which is a
calcium release channel in the sarcoplasmic reticulum. A
highly malignant mutation of c.C6737T (p.Ser2246Leu)
causes catecholaminergic polymorphic ventricular tachy-
cardia (CPVT), which can lead to sudden cardiac death
[30].
All four genes were expressed in undifferentiated hPSCs
(Figs. 1 and 5), which is surprising since ACTC1 encodes
for cardiac actin, a CM-specific structural protein (Fig. 5).
The GC content of the region surrounding the polymor-
phisms, gRNA and TTAA sites differs between ADRB2
(64%), GRK5 (56%), ACTC1 (53%), and RYR2 (42%)
(Figs. 2 and 5). Thus, this set provided an opportunity to
test the simplified PiggyBac approach in genes differing
in sequence composition and that were expressed at rela-
tively low levels in hPSCs.
FIG. 3. Gene editing at the ADRB2 locus in hPSCs. (A) Shows representative chromatogram synopses flanking positions
46, 79, and 124–126 of untargeted, mono- and biallelic targeting, and indels. A complete set for step 1 and step 2 targeting is
in Supplementary Figure S2A and B. The table in (B) summarizes the different targeting events identified after step 1
(midpoint; after puromycin selection for clones containing the positive–negative selection cassette) and step 2 (after
ganciclovir selection for clones in which the cassette has been excised). In (C), high-risk OT sites were classified as known
coding or regulatory sequences where gRNAs had full PAM site complementarily and/or fewer than five mismatches with
the target. PCR genotyping showed no evidence for off target events. In (D), random integration was tested. The schematic
shows the stages of targeting and location of PCRed regions. ADRB2 is a control for genomic DNA, while ADBR2-PT and
TK test for the presence of the targeting cassette; results are shown in the gel images. Since no product was identified for
AMP within the pBluescript backbone, qPCR was used and compared against a positive control (pos) comprising plasmid
DNA diluted to the equivalent of single-copy gene level in HUES7 parental DNA. Housekeeping gene was 18S, n = 3 – SD;
****P < 0.001, Dunnett’s test. OT, off target; qPCR, quantitative polymerase chain reaction. Color images available online
at www.liebertpub.com/scd
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Each gene was targeted in a different hPSC line out of
necessity. The starting genotypes were hESC (line HUES7)
GRK5122A/A, hiPSC ACTC1301G/G from a healthy individ-
ual within a family with familial hypertrophic cardiomy-
opathy, and hiPSC RYR26737C/T from a young patient with
CPVT. In designing the targeting strategies (Fig. 5), we
elected to use endogenous TTAA sites for PiggyBac re-
combination that resided in neighboring introns. In ad-
dition, for each of the three genes (GRK5, ACTC1, and
RYR2), gRNAs were chosen that spanned these TTAA
sites; this means that the gRNAs recognized the endog-
enous genomic sequence but not the targeting vector
because the TTAA demarcates the PiggyBac cassette in-
sertion site (Fig. 5).
Adopting these two strategies allowed production of
true isogenic lines; that is, no further sequence changes with
potentially unknown effects were required either to form a
de novo TTAA site or to protect the targeting vector from
gRNA/Cas9 cleavage. The potential disadvantage of this
approach is that the distance between gRNA/Cas9 cleavage
site and the desired polymorphic change is increased,
which raises the likelihood of recombination occurring
between these two locations and hence not carrying the
polymorphic change into the genome. Indeed, while the
distance between PAM site and polymorphic change was
107 and 136 bp for GRK5122A/A and RYR26737C/T, re-
spectively, it was 313 bp for ACTC1301G/G (Fig. 4).
Targeting vectors were constructed for these genes (Figs. 4
and 5A) using the same design principles that were used for
ADRB2 and thus relied on *2 kb of total homology, with
*1 kb in each of the left and right arms (Fig. 1). Following
positive (puromycin) and then negative (ganciclovir) selec-
tion, colonies were expanded for PCR and sequence analysis
(Fig. 5C). For all three genes, successful targeting of the
polymorphisms to the left arms was observed with concurrent
excision of the PiggyBac selection cassette and reconstitution
of the endogenous TTAA site (Fig. 5C, D). However, the tar-
geting efficiencies differed considerably (Fig. 5D). In GRK5,
genomic cleavage was confirmed in 93% clones, of which 13%
and 47% were monoallelic and biallelic targeting events, re-
spectively. This overall trend of correct targeting was similar to
ACTC1, where cleavage was 75%, although this led to 67%
and 0% monoallelic and biallelic targeting events, respec-
tively. In contrast, cleavage was only evident in 8% of RYR2
clones, which converted to a successful editing event. In
summary, the simplified approach was used to produce
footprint-free, isogenic pairs for four cardiac-related genes
in hPSCs.
Characterization of gene edited hPSCs
Although correct targeting had been achieved, it was im-
portant to confirm whether specific pluripotency and dif-
ferentiation characteristics were retained in ADRB2, GRK5,
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FIG. 5. Gene editing at the GRK5, ACTC1, and RYR2 loci in hPSCs. The schematics in (A) show the loci for each gene
before and after editing, with damaging (black to red; ACTC1), protective (red to black; GRK5), or rescue (red to black;
RYR2) polymorphisms introduced. L and R represent the left and right regions of homology, while primer locations for g, a,
and r are indicated (full details in Supplementary Table S1). In (B), semiquantitative RT-PCRs were carried out for each
gene in undifferentiated hPSCs (Un) and CMs at day 30 of differentiation (CM). Bands were quantified by densitometry and
normalized to b-actin (ACTB) as a housekeeping gene. M, marker; n = 2, errors are – SD. (C) shows representative chro-
matogram synopses flanking polymorphic positions for each gene, while editing efficiencies are displayed in the tables in
(D). Note that for RYR2, it is not possible to tell whether the event was mono- or biallelic, hence the ?? symbols. RT-PCR,
reverse transcription-polymerase chain reaction. Color images available online at www.liebertpub.com/scd
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ACTC1, and RYR2 gene-edited hPSC lines. Representative
examples are shown (Fig. 6), but similar results were obtained
from multiple clones, with the exception of RYR2 where only
one successful targeting event was identified. In all cases,
immunostaining coupled with high-content image analysis
showed that almost all cells expressed the pluripotency marker,
OCT4. This was supported by flow cytometry, where 78%–
99% and 76%–100% of hPSCs being positive for TRA-1-81
and SSEA4, whereas <3% displayed the differentiation mar-
ker, SSEA1 (Fig. 6).
The metaphase spreads of 30 cells per line were assessed
by G-banding karyotyping. Assembly of homologous chro-
mosomes into a karyogram showed no evidence of aberra-
tion. Finally, directed monolayer differentiation was used on
each line to induce beating sheets of CMs. These were
dispersed on day 12–15 of differentiation and stained with
a-actinin, before using high-content image analysis to show
CM purity was between 88% and 98%. Thus, the edited
lines retained key characteristics of pluripotency, most no-
tably differentiation to functional CMs.
Evaluating consequences of GRK5-L41
and –Q41 variants on hPSC-CM function
To demonstrate the utility of isogenic sets of hPSC lines,
we selected wild-type GRK5122A/A and homozygote-edited
GRK5122T/T lines, which differ only in leucine (L) or glutamine
(Q) at position 41 of the encoded peptide. It has been sug-
gested that the GRK5-L41 variant acts as a natural b-blocker
and so is protective against adrenergic stress in the heart
[28]. Therefore, we seeded confluent monolayers of CMs de-
rived from the GRK5 isogenic lines onto the CardioExcyte-96
impedance platform to assess beating characteristics during
chronic (up to 50 h) stimulation with the b-adrenoceptor
agonist, isoprenaline (Fig. 7).
During the first 30 h of isoprenaline treatment, CMs from
both variants showed similar responses with maximum beat
rates reaching *150% of baseline values (Fig. 7Ai, Aii).
This similarity was confirmed by calculating normalized
beat rate (GRK5-Q41 divided by GRK5-L41), which gave
values of close to 1 (Fig. 7Aiii). However, from 30 h on-
ward, the normalized rate of GRK5-Q41 declined, finally
reaching 60%–80% of baseline by the 38–48 time window.
In contrast, by the end of the evaluation period, GRK5-L41
maintained an average rate of 150%, which was reflected
in a Q41/L41 response ratio of *0.5 (note arrows in
Fig. 7Ai–Aiii). This mirrors in vivo findings, which show
that, unless compensation mechanisms can be invoked, pro-
longed (>30 h) activation of adrenoceptors by catecholamines
compromises CM recovery [28].
Since the GRK5-L41 variant has been suggested to im-
part a mild protective effect during chronic b-adrenergic
stimulation, we reran the experiment but this time with
coincubation of isoprenaline and the nonspecific b-blocker,
FIG. 6. Retention of pluripotency characteristics in the edited hPSC lines. (A–C) Show assessment of pluripotency
characteristics in undifferentiated cells from each of the edited lines. This included (A) immunostaining for the transcription
factor, OCT4 [green; inset with DAPI (blue) counterstaining], (B) flow cytometry for TRA-1-81 (blue), SSEA4 (green), and
SSEA1 (red), relative to unstained ( purple), and (C) G-banding karyotyping of 30 metaphase spreads per line, with a
representative karyogram shown for each. In (D), directed monolayer differentiation produced CMs of >88% purity, as
gauged by immunostaining for a-actinin (red) relative to total nuclei count (DAPI, blue). Scale bar is 100 mm; n = 2–4, SD.
Color images available online at www.liebertpub.com/scd
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propranolol (Fig. 7B). As expected, the initial chronotropic
response of both variants was subdued by propranolol.
Notably, however, the chronic decline in beat rate to well
below baseline levels seen by 38–48 h in GRK5-Q41 with
isoprenaline alone (Fig. 7Bi) was abolished with the addition
of propranolol (Fig. 7Bii) and was reflected by response rate
ratios of close to 1 throughout the timecourse (Fig. 7Biii).
Thus, chronic overstimulation of the b-adrenoceptor sys-
tem eventually caused a decline in beat rate in GRK5-Q41,
but not GRK5-L41 hPSC-CMs, and this could be reversed
by b-blockade. This provides a tool for mechanistic under-
standing of genotype–phenotype interactions, which we are
now investigating.
Discussion
We successfully demonstrated a simplified footprint-free
approach to gene edit four distinct cardiac-associated loci in
hPSCs, with modifications, including mono- and/or biallelic
targeting. This included introducing polymorphic changes
in hESC and/or hiPSC lines that were anticipated to be
mildly beneficial to CM function into ADRB2 and GRK5 or
severely damaging into ACTC1. We also corrected a dam-
aging mutation in the RYR2 gene. The edited hPSC lines
retained the ability to undergo high efficiency differentiation
to CMs, enabling us to demonstrate the utility of this ap-
proach by showing functional differences in drug response
for the GRK5 isogenic set. This simplified PiggyBac ap-
proach is easily adaptable to other loci, providing there
is appropriate proximity of TTAA sites, either native or
modified by engineering. Applicability will be irrespec-
tive of whether the targeting strategy uses conventional or
nuclease (eg, zinc fingers, TALE, Cas9/CRISPR) strate-
gies and will be of future value in facilitating mechanistic
studies.
The need for isogenic hPSC lines was highlighted recently
by Sala et al. [3]. Comparison of action potential duration 90
(APD90), an electrophysiology parameter, in CMs derived
from 18 hPSC lines showed more than a fourfold difference,
with values ranging from *140 to 600 ms. Even between
different commercial suppliers of hPSC-CMs, where quality
control is high before release to customers, the range was 225
to 600 ms. A notable departure from this variation was one
isogenic pair, where CMs from both lines had highly similar
APD90 values of *230 ms.
Contextually, the normal range for humans APD90 values
(usually cited as QT interval) is 350–450 ms, and increases
of 10%–20% are worrisome. During drug development,
such prolongation would likely lead to the termination of the
drug [31]. Clinically, QT intervals of >460–500 ms usually
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FIG. 7. Functional effects of chronic isoprenaline on GRK5-L41 and –Q41 hPSC-CMs. Using the CardioExcyte im-
pedance platform, the beat rate of the edited hPSC-CM lines was monitored at *10 min intervals during chronic stimulation
(*50 h) with 100 nM isoprenaline (Iso; Ai, Aii) with or without beta-blockade with 200 nM propranolol (Prop; Bi, Bii).
Data were binned for the periods shown and plotted as normalized to percent change from BL. The response ratios were
calculated by dividing each datum from GRK5-Q41 by the corresponding time point from GRK5-L41 hPSC-CMs with-
out (Aiii) or with (Biii) blockade with propranolol. Arrowhead indicates where there is a highly significant decline in the
beat rate of the GRK5-Q41 hPSC-CMs. Dunnett’s test relative to BL: *P< 0.05; **P< 0.01; ***P < 0.001; ****P< 0.0001.
BL, baseline. Color images available online at www.liebertpub.com/scd
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signify disease state, such as long QT syndrome, which is
caused by mutations in various ion channel proteins and can
lead to sudden cardiac death [32]. This means that depending
on the hPSCs selected, the phenotypic variation between lines
(up to 400%) can be greater than any change caused by the
mutation (usually 10% to 100%). This may explain some
of the discrepancies reported in the literature for hPSC-
based disease modeling, including for the magnitude of
change caused by mutations in KNCQ1, which underlies
long-QT syndrome type 1 [33,34]. Consequently, the use
of isogenic pairs is becoming the gold standard for disease
modeling using hPSCs. The isogenic approach allows de-
sired polymorphisms to be studied within the same genetic
background and the ‘‘noise’’ is eliminated from the other
estimated *11 million single nucleotide polymorphisms
(SNPs), 2.8 million short indels, and *500,000 block
substitutions that exist between unrelated individuals [35].
A true isogenic pair will differ only in the desired poly-
morphic change. Part or whole remnants of selection cas-
settes can perturb gene function [36], even when positioned
in introns because of the presence of currently unannotated
sequences. Indeed, in hPSCs, we found that even when
Cas9/CRISPR was used to target Ef1a-driven blasticidin or
puromycin resistance markers into neighboring introns, this
abolished expression of KCNH2 [1] and MYH7 (Supple-
mentary Fig. S3C) genes encodes the HERG potassium ion
channel and beta myosin heavy-chain structural protein,
respectively. In both cases, cassette removal restored ex-
pression of KCNH2 and MYH7. For ADRB2, the complexity
of the locus and absence of a nearby TTAA site necessitated
conversion of CTC ATC to TTA ATC. In humans, both CTC
and TTA are compatible with the leucine tRNA machinery
but the probability of use is 0.2 and 0.07, meaning that
CTC is preferred. Also, current gene annotation shows this
change should not interfere with control regions (promoters,
enhancers, noncoding RNAs, splice sites, etc.), but needs
to be borne in mind during targeting design. Thus, any
changes, from single bases through to residual sequences
([1,37,38]; Supplementary Fig. S3), may need thorough
investigation to rule out any potential negative impact on
cell function.
For loci that are more refractory to targeting, cultures can
be pooled at the midpoint of the process (after step 1/pu-
romycin treatment) and an aliquot of cells taken for bulk
PCR analysis. Primers are chosen to span from the selection
cassette to the flanking genomic region of the locus of in-
terest. If no PCR product is produced, this may suggest that
the experiment should be abandoned. However, if there is a
product, then, the cells can be reseeded, transfected with
transposase, and then treated with ganciclovir to finish the
excision/colony selection process.
A surprising observation was that when cells at
this puromycin-resistant midpoint were cryopreserved,
the positive–negative selection cassette was silenced upon
thawing of the cells; this occurred across several loci
beyond those described in this report. We are unsure as
to why the cryopreservation–thaw cycle caused this ef-
fect. Indeed, it is well documented that silencing of
transgenes occurs readily in hPSCs, particularly when
nonmammalian promoters are used [39]. However, we
used the mammalian promoter, phosphoglycerate kinase,
which is usually well tolerated [40,41]. We are not aware
of other reports where transgene expression is maintained
during long-term culture, unless a cryopreservation–thaw
cycle is introduced.
Although all loci were targeted successfully, there were
notable differences. Genome editing occurred at an effi-
ciency of 42%–67% in ADRB2, GRK5, and ACTC1, but
only 8% in RYR2. All the genes were expressed, but this is
not a prerequisite for Cas9/CRISPR targeting. Our data for
MYH7 showed a frequency of mono- and biallelic events
totaled *25% (Supplementary Fig. S3). In terms of GC
content, RYR2 had the lowest (42%) around the target site,
which might be expected to give better access for gene
targeting rather than the lowly 8% reported in this study.
This may be because the complexity of the RYR2 locus is
high, with regions flanking the target site, including repet-
itive elements (LINE, SINE, Alu). Another parameter that
could influence targeting efficiency is the cell line used. Out
of necessity, we used different hPSC lines because of their
starting genotype, which in some cases was disease- or
patient-specific. Many similarities and differences have been
reported between hPSC lines [16]. In our report, we found
that the puromycin concentration required during selection
varied from 0.25 to 7.5 mg/mL. Thus, it would be unsur-
prising if variation extended to differential targeting effi-
ciencies between hPSC lines.
Vector construction and lengths of homology regions
are also factors known to impact targeted recombination
[42]. The same design principles were used for all four
loci, but the distances between the PAM site in the gRNA
and polymorphism (termed PAM-SNP) varied out of ne-
cessity. Differences in targeting frequency may be ex-
plained by the mechanism of repair. DNA repair occurs
via multiple pathways or subpathways, including DNA
double-strand break repair (DSBR), Holliday junction
dissolution, synthesis-dependent strand annealing, and
single-strand DNA incorporation [43,44]. With regard to
DSBR, long conversion tracts (approximately –1 kb) are
generated either side of the of conversion zone, with
probability of conversion decreasing as a function of
PAM-SNP distance [45]. Linear dependency also occurs
with ssODNs [9,43], but creates conversion tracts of ap-
proximately –60 nucleotides [43], which is why this ap-
proach tends to only incorporate small insertions or
substitutions.
The PAM-SNP frequency-distance relationship may
explain some of the differences in nature and efficiency of
targeting events. For ACTC1, with a 300 nucleotide dis-
tance, there was a higher probability of recombination
occurring between PAM site and polymorphism. After
transposase-mediated cassette excision, the sequence in the
final chromatogram would appear as untargeted because
the approach was designed to be footprint-free. This may
have contributed to a profile of clones being untargeted =
high (25%), monoallelic targeted = high (67%), and bial-
lelic targeted = low (0%). In contrast, the short PAM-SNP
distance of around 100 nucleotides or less for ADRB2 and
GRK5 presented profiles of 0%, 8%, and 33% and 8%,
13%, and 47%, respectively. Fortuitously, only heterozy-
gote mutations occur in humans for ACTC1, presumably
because it would likely lead to early lethality, which is
the case in mouse knockouts. However, the PAM-SNP
distance is clearly not the only factor, since most (92%)
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clones for RYR2 were not targeted. We cannot be sure
whether the one RYR2 clone was mono- or biallelic tar-
geting event since the template was identical to the
healthy allele, so only correction of the mutant allele
could be detected.
Our main goal in this work was to reduce the duration
required to produce isogenic sets of hPSCs, with a specific
emphasis on in vitro disease modeling of the cardiovascular
system. While others have used the PiggyBac system, we
describe an abbreviated version that not only saves time and
effort but also the number of population doublings required
to produce the gene-edited cells. This is important because
both empirical experimentation [14] and mathematical
modeling [46] show that genetic and epigenetic changes are
inevitable as a function of time.
The targeted clones in this study were examined by
karyotyping of at least 30 metaphase spreads. Never-
theless, further detailed analysis will be needed to examine
the broader stability of these lines. The rate of epigenetic
change is highest soon after hESC line derivation, with
most changes being haphazard [14,15]. In contrast, many
genetic changes are predictable. This is exemplified by a
large-scale study [14] of 136 hESC and hiPSC lines from
38 laboratories worldwide, which showed a progressive
tendency to acquire changes on prolonged culture. Com-
mon changes at the chromosome level were part or whole
gains of 1, 12, and/or 17. However, in *20% of lines
studied, there was also gain of a minimal amplicon in
chromosome 20q11.21. This included three genes, ID1,
BCL2L1, and HM13, with BCL2L1 driving a selective
advantage for hPSC survival in culture. Whether stochastic
or nonstochastic, these changes may affect the quality of
the cells for biomedical application. Strategies to reduce
the population doublings required during their manipula-
tion should be welcomed, although to date this has not
been considered. This would bring genetically engineered
hPSCs into kilter with the international guidelines for
clinical grade lines, where low-passage seed stocks or
master banks are recommended [47].
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